Sakarya Phase 1 is a producing conventional gas field located in ultra-deepwater in Turkey and is operated by Turkiye Petrolleri Anonim Ortakligi. According to GlobalData, who tracks more than 34,000 active and developing oil and gas fields worldwide, the field is located in block C26,C27,D26,D27, with water depth of 12,956 feet. Buy the profile here.
An expansion project is associated with the Sakarya Phase 1, namely the Amasra Development. This project is currently in the feasibility stage.
Field participation details
The field is owned by Turkiye Petrolleri Anonim Ortakligi.
Production from Sakarya Phase 1
The Sakarya Phase 1 conventional gas field recovered 1.68% of its total recoverable reserves, with peak production expected in 2025. Based on economic assumptions, production will continue until the field reaches its economic limit in 2049. The field currently accounts for approximately 12% of the country’s daily output.
About Turkiye Petrolleri Anonim Ortakligi
Turkiye Petrolleri Anonim Ortakligi (TPAO) is an oil and gas company that carries out exploration, refining, and marketing services for oil and gas. The company offers services such as geological services, seismic services, drilling, and domestic and international oil and natural gas production services. Its geological services are used in geological field surveys. TPAO offers various exploration services which include seismic data, non-seismic data acquisition, seismic process applications, interpretation systems, GIS and remote sensing applications. The company also works as an enhanced oil recovery project. It has a presence in Azerbaijan, Turkey, Kazakhstan, Syria, Iraq and Libya. TPAO is headquartered in Ankara, Turkiye.
For more details on the Sakarya Phase 1 Conventional Gas Field, buy the profile here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.